SCHEMBL3377007

SCHEMBL3377007

CS(=O)(=O)Nc1ccc(-c2ccc(F)cc2F)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KIT P10721 5/20 0.51
GAA P10253 1/20 0.49
HPGD P15428 1/20 0.49
MAPK1 P28482 1/20 0.49
CYP17A1 P05093 1/20 0.48
HAVCR2 Q8TDQ0 2/20 0.46
PGR P06401 1/20 0.45
FABP4 P15090 2/20 0.44
FABP5 Q01469 2/20 0.44
HSD17B3 P37058 1/20 0.43
HSD17B2 P37059 1/20 0.43
ADRA2C P18825 1/20 0.42
ADRA1A P35348 1/20 0.42
ADRA1B P35368 1/20 0.42
BRD4 O60885 1/20 0.42
KIF11 P52732 1/20 0.41
MAP2K4 P45985 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3375774 0.92 GAA (0.52) KITGAAHPGDMAPK1CYP17A1
SCHEMBL3379958 0.85 GAA (0.49) GAAHPGDMAPK1CYP17A1HAVCR2
SCHEMBL3378764 0.84 PTGS2 (0.51) KITGAAHPGDMAPK1CYP17A1
SCHEMBL3374111 0.81 GAA (0.50) KITGAAHPGDMAPK1CYP17A1
SCHEMBL3378891 0.80 SLC22A12 (0.52) GAAHPGDMAPK1CYP17A1PGR
SCHEMBL3379785 0.79 GAA (0.49) KITGAAHPGDMAPK1CYP17A1
SCHEMBL11233219 0.79 MEN1 (0.55) GAAHPGDMAPK1ADRA2CADRA1A
SCHEMBL3376954 0.78 KIF11 (0.48) KITGAAHPGDMAPK1CYP17A1
SCHEMBL3374747 0.78 KIF11 (0.51) KITGAAHPGDMAPK1CYP17A1
SCHEMBL3377083 0.78 PTGS2 (0.52) GAAHPGDMAPK1CYP17A1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US claimed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO claimed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US claimed
US-8389500-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2013-03-05 US disclosed
WO-2010056527-A2 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-20 WO disclosed
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD PALO ALTO, INC. (US) 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113449-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, HCN4, KCNH2 KIT 4087/4885GAA 1564/4885HPGD 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.